Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis

被引：131

作者：

Taylor, Peter C. ^{[1
]}

机构：

[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Windmill Rd, Oxford OX3 7LD, England

来源：

RHEUMATOLOGY | 2019年 / 58卷

关键词：

Janus kinase; rheumatoid arthritis; efficacy; tofacitinib; baricitinib; small-molecule kinase inhibitor; symptoms and signs; structural damage; function; patient reported outcomes; PATIENT-REPORTED OUTCOMES; MODIFYING ANTIRHEUMATIC DRUGS; TOFACITINIB MONOTHERAPY; INADEQUATE RESPONSE; RANDOMIZED PHASE-3; TREATED PATIENTS; DOUBLE-BLIND; METHOTREXATE; BARICITINIB; ADALIMUMAB;

D O I：

10.1093/rheumatology/key225

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of Janus kinase (JAK) enzymes to be approved for the treatment of RA. Tofacitinib is a selective JAK1, 3 inhibitor with less activity against JAK2 and TYK2 and baricitinib is a selective, oral JAK1, 2 inhibitor with moderate activity against TYK2 and significantly less activity against JAK3. Both drugs have undergone extensive phase III clinical trials in RA and demonstrated rapid improvements in disease activity, function and patient-reported outcomes as well as disease modification. Tofacitinib 5 mg bd, was approved by the Federal Drug Administration in 2012 for the treatment of RA in patients who are intolerant or unresponsive to MTX. An extended release formulation for the treatment of RA was approved by Federal Drug Administration in 2016. In 2017 the European Medicines Agency approved tofacitinib 5 mg bd in combination with MTX and baricitinib 4 mg and 2 mg once daily for the treatment of moderate to severe active RA in adult patients who are intolerant or unresponsive to one or more conventional synthetic DMARDs.

引用

页码：17 / 26

页数：10

共 47 条

[1]

The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[2]

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J].

Burmester, Gerd R. ;

Blanco, Ricardo ;

Charles-Schoeman, Christina ;

Wollenhaupt, Juergen ;

Zerbini, Cristiano ;

Benda, Birgitta ;

Gruben, David ;

Wallenstein, Gene ;

Krishnaswami, Sriram ;

Zwillich, Samuel H. ;

Koncz, Tamas ;

Soma, Koshika ;

Bradley, John ;

Mebus, Charles .

LANCET, 2013, 381 (9865) :451-460

[3]

Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor [J].

Charles-Schoeman, Christina ;

Wicker, Pierre ;

Gonzalez-Gay, Miguel A. ;

Boy, Mary ;

Zuckerman, Andrea ;

Soma, Koshika ;

Geier, Jamie ;

Kwok, Kenneth ;

Riese, Richard .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 46 (03) :261-271

[4]

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases [J].

Clark, James D. ;

Flanagan, Mark E. ;

Telliez, Jean-Baptiste .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) :5023-5038

[5]

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [J].

Dougados, Maxime ;

van der Heijde, Desiree ;

Chen, Ying-Chou ;

Greenwald, Maria ;

Drescher, Edit ;

Liu, Jiajun ;

Beattie, Scott ;

Witt, Sarah ;

de la Torre, Inmaculada ;

Gaich, Carol ;

Rooney, Terence ;

Schlichting, Douglas ;

de Bono, Stephanie ;

Emery, Paul .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :88-95

[6]

CHARACTERISATION OF CHANGES IN LYMPHOCYTE SUBSETS IN BARICITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS IN TWO PHASE 3 STUDIES [J].

Emery, P. ;

McInnes, I. ;

Genovese, M. C. ;

Smolen, J. S. ;

Kremer, J. ;

Dougados, M. ;

Schlichting, D. E. ;

Rooney, T. ;

Issa, M. ;

de Bono, S. ;

Macias, W. L. ;

Rogai, V. ;

Zuckerman, S. H. ;

Taylor, P. C. .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 :A62-A62

[7]

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial [J].

Fleischmann, Roy ;

Mysler, Eduardo ;

Hall, Stephen ;

Kivitz, Alan J. ;

Moots, Robert J. ;

Luo, Zhen ;

DeMasi, Ryan ;

Soma, Koshika ;

Zhang, Richard ;

Takiya, Liza ;

Tatulych, Svitlana ;

Mojcik, Christopher ;

Krishnaswami, Sriram ;

Menon, Sujatha ;

Smolen, Josef S. .

LANCET, 2017, 390 (10093) :457-468

[8]

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment [J].

Fleischmann, Roy ;

Schiff, Michael ;

van der Heijde, Desiree ;

Ramos-Remus, Cesar ;

Spindler, Alberto ;

Stanislav, Marina ;

Zerbini, Cristiano A. F. ;

Gurbuz, Sirel ;

Dickson, Christina ;

de Bono, Stephanie ;

Schlichting, Douglas ;

Beattie, Scott ;

Kuo, Wen-Ling ;

Rooney, Terence ;

Macias, William ;

Takeuchi, Tsutomu .

ARTHRITIS & RHEUMATOLOGY, 2017, 69 (03) :506-517

[9]

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis [J].

Fleischmann, Roy ;

Kremer, Joel ;

Cush, John ;

Schulze-Koops, Hendrik ;

Connell, Carol A. ;

Bradley, John D. ;

Gruben, David ;

Wallenstein, Gene V. ;

Zwillich, Samuel H. ;

Kanik, Keith S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :495-507

[10]

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis [J].

Fleischmann, Roy M. ;

Huizinga, Tom W. J. ;

Kavanaugh, Arthur F. ;

Wilkinson, Bethanie ;

Kwok, Kenneth ;

DeMasi, Ryan ;

van Vollenhoven, Ronald F. .

RMD OPEN, 2016, 2 (02)

← 1 2 3 4 5 →